- Home
- CRVO vs NEPH Comparison
CRVO vs NEPH Comparison
Compare CRVO & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- NEPH
- Stock Information
- Founded
- CRVO 2001
- NEPH 1997
- Country
- CRVO United States
- NEPH United States
- Employees
- CRVO N/A
- NEPH N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- NEPH Medical/Dental Instruments
- Sector
- CRVO Health Care
- NEPH Health Care
- Exchange
- CRVO Nasdaq
- NEPH Nasdaq
- Market Cap
- CRVO 65.2M
- NEPH 60.4M
- IPO Year
- CRVO N/A
- NEPH 2004
- Fundamental
- Price
- CRVO $7.58
- NEPH $4.37
- Analyst Decision
- CRVO Strong Buy
- NEPH Strong Buy
- Analyst Count
- CRVO 6
- NEPH 2
- Target Price
- CRVO $21.50
- NEPH $5.50
- AVG Volume (30 Days)
- CRVO 64.4K
- NEPH 68.7K
- Earning Date
- CRVO 11-10-2025
- NEPH 11-06-2025
- Dividend Yield
- CRVO N/A
- NEPH N/A
- EPS Growth
- CRVO N/A
- NEPH N/A
- EPS
- CRVO N/A
- NEPH 0.14
- Revenue
- CRVO $6,159,786.00
- NEPH $17,930,000.00
- Revenue This Year
- CRVO N/A
- NEPH $24.38
- Revenue Next Year
- CRVO N/A
- NEPH $10.16
- P/E Ratio
- CRVO N/A
- NEPH $32.34
- Revenue Growth
- CRVO N/A
- NEPH 32.36
- 52 Week Low
- CRVO $1.80
- NEPH $1.39
- 52 Week High
- CRVO $16.94
- NEPH $5.98
- Technical
- Relative Strength Index (RSI)
- CRVO 54.12
- NEPH 42.66
- Support Level
- CRVO $6.56
- NEPH $3.66
- Resistance Level
- CRVO $7.80
- NEPH $4.72
- Average True Range (ATR)
- CRVO 0.46
- NEPH 0.55
- MACD
- CRVO 0.11
- NEPH -0.14
- Stochastic Oscillator
- CRVO 87.86
- NEPH 35.93
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.